Form 4: Camp4 Therapeutics CFO Kelly Gold Granted Stock Options

Camp4 Therapeutics CFO Kelly Gold was granted 190,000 stock options with an exercise price of $6.01, vesting over three years.

Summary

• Kelly Gold, Chief Financial Officer of Camp4 Therapeutics Corp. (CAMP), was granted 190,000 stock options.
• The options have an exercise price of $6.01 per share.
• The transaction date for this grant was December 11, 2025.
• The options have a vesting start date of December 1, 2025.
• Vesting occurs as to one-third (33.33%) of the shares on the first anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments over the subsequent 24 months, subject to continued service.
• The expiration date for these stock options is December 10, 2035.
• The options represent a right to buy 190,000 shares of Common Stock.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal as it aligns management's interests with shareholders. It incentivizes long-term performance and retention. However, it does not represent immediate financial gain for the company or a direct improvement in operational metrics, hence a moderate positive score.

Positives

• The grant of stock options aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing company performance.
• The options have a long expiration date (December 10, 2035), providing a significant window for potential value realization.

Negatives

• The options are not immediately exercisable and are subject to a vesting schedule, meaning the benefit is contingent on future service and stock performance.
• The exercise price of $6.01 means the stock price must exceed this value for the options to be 'in the money' and hold intrinsic value.

Future Outlook

The grant of stock options to the Chief Financial Officer is a forward-looking incentive, aligning management's financial interests with the company's future performance and shareholder value creation over the vesting and option term.

Industry Context

The grant of stock options to key executives like the CFO is a standard and widely adopted practice in the biotechnology and pharmaceutical industries, as well as across many public companies, to attract, retain, and motivate talent by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• This type of stock option grant, with a multi-year vesting schedule and a long expiration term, is a common component of executive compensation packages across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The structure aims to incentivize long-term commitment and performance, similar to practices seen at comparable early-stage or mid-cap biotech firms where executive compensation often includes a significant equity component.

Related Party Transactions

• The transaction involves the grant of stock options to Kelly Gold, the Chief Financial Officer, which is a related-party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's financial incentives with shareholder value creation, potentially leading to more focused efforts on increasing stock price.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.
• Management: Provides a significant long-term incentive for the CFO to remain with the company and contribute to its success.

Next Steps

• The options will begin vesting according to the specified schedule, with the first tranche vesting on December 1, 2026 (one year after the vesting start date).
• The remaining options will vest in equal monthly installments over the subsequent 24 months, contingent on Kelly Gold's continued service.

Key Dates

Recommendation

The Form 4 filing details a routine executive compensation event—the grant of stock options to the CFO. While this action positively aligns management's long-term interests with those of shareholders, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in an investment thesis. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while continuing to monitor broader company developments and market conditions.

Keywords

Camp4 Therapeutics, CAMP, Stock Option, Insider Transaction, Form 4, Kelly Gold, CFO, Executive Compensation